In patients with urological cancers and melanoma, SSTR2 expression by IHC has been reported as positively correlated with the response to a checkpoint blockade, suggesting SSTR2 as a potential surrogate marker to identify responders to immunotherapy. Here, SSTR2 is linked to melanoma.